Capstone Therapeutics (CAPS) Competitors $1.25 -0.03 (-2.34%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CAPS vs. RENB, TENX, DARE, RNTX, KZR, CVKD, AKTX, MTVA, LIXT, and ENLVShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Lunai Bioworks (RENB), Tenax Therapeutics (TENX), Dare Bioscience (DARE), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Akari Therapeutics (AKTX), MetaVia (MTVA), Lixte Biotechnology (LIXT), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors Lunai Bioworks Tenax Therapeutics Dare Bioscience Rein Therapeutics Kezar Life Sciences Cadrenal Therapeutics Akari Therapeutics MetaVia Lixte Biotechnology Enlivex Therapeutics Lunai Bioworks (NASDAQ:RENB) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk. Which has better earnings & valuation, RENB or CAPS? Capstone Therapeutics has higher revenue and earnings than Lunai Bioworks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLunai BioworksN/AN/A-$88.43M-$0.77-0.17Capstone Therapeutics$44.88M0.18-$2.56MN/AN/A Do institutionals & insiders have more ownership in RENB or CAPS? 71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 42.8% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, RENB or CAPS? Lunai Bioworks has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -0.81, meaning that its share price is 181% less volatile than the S&P 500. Is RENB or CAPS more profitable? Capstone Therapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Lunai BioworksN/A -60.38% -47.04% Capstone Therapeutics N/A N/A N/A Does the media refer more to RENB or CAPS? In the previous week, Lunai Bioworks had 7 more articles in the media than Capstone Therapeutics. MarketBeat recorded 8 mentions for Lunai Bioworks and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.95 beat Lunai Bioworks' score of 0.17 indicating that Capstone Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lunai Bioworks Neutral Capstone Therapeutics Positive SummaryCapstone Therapeutics beats Lunai Bioworks on 6 of the 9 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.89M$3.11B$5.66B$10.37BDividend YieldN/A2.39%5.75%4.64%P/E RatioN/A21.3275.7526.15Price / Sales0.18454.84560.95125.53Price / CashN/A45.2537.6061.28Price / Book-0.069.7412.416.36Net Income-$2.56M-$52.93M$3.29B$270.97M7 Day Performance-10.71%3.87%1.26%0.36%1 Month Performance-11.97%7.65%3.84%6.37%1 Year PerformanceN/A20.14%61.01%28.46% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.25-2.3%N/AN/A$7.89M$44.88M0.0038RENBLunai Bioworks0.7723 of 5 stars$0.18+8.2%N/A-72.0%$30.12MN/A-0.2320News CoverageUpcoming EarningsStock SplitGap UpHigh Trading VolumeTENXTenax Therapeutics2.4574 of 5 stars$6.41flat$18.00+180.8%+94.6%$29.25MN/A-6.979Positive NewsDAREDare Bioscience2.2359 of 5 stars$2.12+1.9%$10.00+371.7%-36.6%$28.58M$10K-0.9930RNTXRein Therapeutics2.4705 of 5 stars$1.21+5.2%N/AN/A$28.20MN/A-0.459News CoverageAnalyst RevisionGap DownKZRKezar Life Sciences3.8324 of 5 stars$3.76flat$9.00+139.4%-31.7%$27.53M$7M-0.3960Positive NewsCVKDCadrenal Therapeutics3.4555 of 5 stars$13.17-1.3%$32.00+143.0%+1.4%$26.96MN/A-1.484Positive NewsAKTXAkari Therapeutics3.5214 of 5 stars$0.81+1.5%$3.30+306.2%-64.6%$26.50MN/A0.009MTVAMetaVia2.1831 of 5 stars$1.04+13.4%$7.50+621.2%N/A$25.17MN/A0.008Gap DownLIXTLixte Biotechnology1.1309 of 5 stars$5.45+0.6%N/A+186.9%$24.86MN/A-4.224Gap DownENLVEnlivex Therapeutics2.4009 of 5 stars$1.05-0.5%$10.00+856.9%-29.0%$24.72MN/A-1.8070Analyst Forecast Related Companies and Tools Related Companies RENB Alternatives TENX Alternatives DARE Alternatives RNTX Alternatives KZR Alternatives CVKD Alternatives AKTX Alternatives MTVA Alternatives LIXT Alternatives ENLV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPS Stock Alerts